Home' Australian Pharmacist : Australian Pharmacist November 2016 Contents Australian Pharmacist November 2016 I ©Pharmaceutical Society of Australia Ltd.
CONTINUING PROFESSIONAL DEVELOPMENT
SOLUTIONS THROUGH COMPOUNDING
1. Omeprazole, not available as an
oral liquid and requiring to be
compounded, presents a challenge
to pharmacists because:
a) Omeprazole is susceptible to
degradation, especially under alkaline
b) Dispersion of tablets in water as an
alternative to a compounded product
results in an extremely bitter-tasting
product, which is unacceptable
especially to children.
c) Adjusting the paediatric dosage of
a granule-containing omeprazole
formulation by weight is easy.
d) Enteric-coated granules, when
dispersed in water and not
compounded, may be chewed by
children resulting in increased efficacy.
2. Storage of omeprazole suspension
to ensure optimum stability should
include protection from light at:
a) <25 °C.
b) <30 °C.
c) 2–8 °C.
d) -18 °C.
3. Factors that need to be taken into
account when flavouring and
sweetening medicines for children
a) A less-developed sensory system for
detecting tastes, smells and chemical
b) Addition of volatile flavours such
as bubble gum, which are not only
favourable, but effective at suppressing
the bitter taste associated with some
active pharmaceutical ingredients (APIs).
c) Achievement of universally appealing
volatile flavouring is difficult due to
variations in cultural preferences.
d) Sucrose, the least commonly used
bulk sweetener, on chronic use may
contribute to dental caries.
4. The role of acesulfame potassium
in the omeprazole 2 mg/mL oral
suspension is as a:
c) Viscosity-increasing agent.
d) Sweetener to mask unpleasant tasting
Omeprazole inhibits CYP2C19 and
increases cilostazol concentration,
therefore combined treatment with
omeprazole and cilostazol should be
avoided. Also avoid use in patients
with allergies to omeprazole or
Other adverse effects, special
precautions, monitoring and practice
points for the use of omeprazole are
outlined in the Australian Medicines
and the APF23.
Advice on lifestyle modifications and
avoidance of precipitating factors
can be provided to adult patients or
Directions for use
Shake well before each use to ensure
an accurate dose.3
Use the measuring device supplied to
accurately measure the required dose.
Take the medicine at the same time
The preparation should be stored
protected from light, in the
refrigerator (2–8 °C),
and kept away
from children and pets.
KEY LEARNING POINTS
Omeprazole suspension may be
compounded by pharmacists to
meet specific patient needs, where
commercial products do not meet
Pharmacists are able to prepare a
suspension that contains appropriate
excipients to ensure the optimum
stability and accurate dosing of
Pharmacists are able to ensure that
suspensions prepared are sweetened
and flavoured appropriately for
the intended patient population,
to improve adherence as well as
ensuring the efficacy of the active
pharmaceutical ingredient (API), e.g.
1. Rossi S, ed. Australian medicines handbook. Adelaide:
Australian Medicines Handbook; 2016.
2. Burnett JE, Balkin ER. Stability and viscosity of a flavored
omeprazole oral suspension for pediatric use. Am J Health
Syst Pharm 2006;63(22):2240–7 .
3. Sansom LN, ed. Australian pharmaceutical formulary and
handbook. 23rd edn. Canberra: Pharmaceutical Society of
4. Block JH, Beale JM. Wilson and Gisvold’s textbook of
organic medicinal and pharmaceutical chemistry. 11th
edn. Philadelphia: Lippincott, Williams and Wilkins; 2004.
5. Graudins LV, Kivi NJ, Tattam BN. Stability of omeprazole
mixtures: implications for paediatric prescribing. J Pharm
Prac Res 2008;38(4):276–79.
6. Phillips JO, Metzler M, Johnson K. The stability of
simplified omeprazole suspension (SOS). Crit Care Med
7. Quercia RA, Fan C, Liu X, et al. Stability of omeprazole in an
extemporaneously prepared oral liquid. Am J Health Syst
Pharm 1997;54(16):1833–6 .
8. DiGiacinto JL, Olsen KM, Bergman KL, et al. Stability of
suspension formulations of lansoprazole and omeprazole
stored in amber-colored plastic oral syringes. Ann
Pharmacother 2000;34(5):600–5 .
9. Whaley PA, Voudrie MA 2nd, Sorenson B. Stability of
omeprazole in SyrSpend SF Alka (reconstituted). Int J Pharm
Compd 2012;16(2):164–6 .
10. Highlights of prescribing information: zegerid powder for
oral suspension and capsules. 2010. At: www.accessdata.
11. Johnson CE, Cober MP, Ludwig JL. Stability of partial doses
of omeprazole-sodium bicarbonate oral suspension. Ann
12. Mennella JA, Beauchamp GK. Optimizing oral medications
for children. Clin Ther 2008;30(11):2120–32.
13. Ali AA, Charoo NA, Abdallah DB. Pediatric drug
development: formulation considerations. Drug Dev Ind
Pharm 2014;40(10):1283–99 .
14. Walsh J, Cram A, Woertz K, et al. Playing hide and seek with
poorly tasting paediatric medicines: do not forget the
excipients. Adv Drug Deliv Rev 2014;73:14–33 .
15. Martindale: the complete drug reference. London:
Pharmaceutical Press; 2015.
16. Rowe RC, Sheskey PJ, Cook WG, et al. Handbook
of pharmaceutical excipients. 7th edn. London:
Pharmaceutical Press; 2012.
17. Carboxymethylcellulose Sodium. US pharmacopeia
national formulary (USP 39-NF 34). Rockville, MD: United
States Pharmacopeial Convention; 2016.
18. Aulton ME. Pharmaceutics: the science of dosage form
design. 2nd edn. London Churchill Livingstone; 2002. p. 42.
19. Pharmaceutical Society of Australia. Professional practice
standards. Version 4. Canberra: PSA; 2010.
Links Archive Australian Pharmacist October 2016 Australian Pharmacist December2016 Navigation Previous Page Next Page